Inhibits ACE with a Ki of 1.6 uM, and targets B2 bradykinin receptor (BDKRB2). Provokes contraction of smooth muscle preparation (ileum). In vivo, induces an early hyperalgesic effects in living rats after intraplantar injection (By similarity). Has bradykinin-like, although lower activities (e.g. smooth muscle contraction). May target bradykinin receptors (BDKRB). Expressed by the venom gland. Belongs to the bradykinin-related peptide family.